iA Global Asset Management Inc. Takes $4.22 Million Position in Zenas BioPharma, Inc. $ZBIO

iA Global Asset Management Inc. purchased a new stake in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the 1st quarter, Holdings Channel reports. The fund purchased 215,830 shares of the company’s stock, valued at approximately $4,219,000.

A number of other institutional investors also recently bought and sold shares of ZBIO. Geode Capital Management LLC increased its position in Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after acquiring an additional 16,461 shares during the last quarter. Rhumbline Advisers grew its holdings in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after purchasing an additional 8,207 shares during the last quarter. Sei Investments Co. purchased a new stake in Zenas BioPharma in the 2nd quarter worth about $118,000. Bank of America Corp DE raised its position in Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after purchasing an additional 3,412 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after purchasing an additional 170,546 shares during the last quarter.

Insider Buying and Selling at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the acquisition, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders bought 120,000 shares of company stock valued at $2,080,000 over the last quarter. 22.00% of the stock is currently owned by corporate insiders.

Zenas BioPharma Trading Up 10.3%

NASDAQ ZBIO opened at $28.00 on Thursday. The company has a fifty day simple moving average of $19.62 and a two-hundred day simple moving average of $23.06. The stock has a market cap of $1.77 billion, a P/E ratio of -3.31 and a beta of -0.97. Zenas BioPharma, Inc. has a 12-month low of $8.91 and a 12-month high of $44.60. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter in the previous year, the business earned ($0.80) EPS. On average, analysts forecast that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZBIO has been the subject of several recent analyst reports. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Wednesday, June 24th. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Morgan Stanley increased their target price on Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.29.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.